Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/FASN_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FASN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FASN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FASN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FASN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FASN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FASN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FASN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FASN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FASN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001969319 | Oral cavity | OSCC | ribose phosphate metabolic process | 199/7305 | 396/18723 | 2.97e-06 | 3.64e-05 | 199 |
GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
GO:000206419 | Oral cavity | OSCC | epithelial cell development | 116/7305 | 220/18723 | 2.34e-05 | 2.21e-04 | 116 |
GO:000925919 | Oral cavity | OSCC | ribonucleotide metabolic process | 189/7305 | 385/18723 | 3.18e-05 | 2.87e-04 | 189 |
GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
GO:000164910 | Oral cavity | OSCC | osteoblast differentiation | 118/7305 | 229/18723 | 7.51e-05 | 5.85e-04 | 118 |
GO:00018859 | Oral cavity | OSCC | endothelial cell development | 40/7305 | 64/18723 | 1.20e-04 | 8.57e-04 | 40 |
GO:007252120 | Oral cavity | OSCC | purine-containing compound metabolic process | 199/7305 | 416/18723 | 1.34e-04 | 9.53e-04 | 199 |
GO:000915020 | Oral cavity | OSCC | purine ribonucleotide metabolic process | 178/7305 | 368/18723 | 1.45e-04 | 1.02e-03 | 178 |
GO:00160537 | Oral cavity | OSCC | organic acid biosynthetic process | 155/7305 | 316/18723 | 1.64e-04 | 1.13e-03 | 155 |
GO:00463947 | Oral cavity | OSCC | carboxylic acid biosynthetic process | 154/7305 | 314/18723 | 1.73e-04 | 1.19e-03 | 154 |
GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
GO:006102816 | Oral cavity | OSCC | establishment of endothelial barrier | 30/7305 | 46/18723 | 2.86e-04 | 1.80e-03 | 30 |
GO:000616320 | Oral cavity | OSCC | purine nucleotide metabolic process | 188/7305 | 396/18723 | 3.31e-04 | 2.04e-03 | 188 |
GO:000315816 | Oral cavity | OSCC | endothelium development | 71/7305 | 136/18723 | 1.18e-03 | 5.99e-03 | 71 |
GO:003022414 | Oral cavity | OSCC | monocyte differentiation | 23/7305 | 36/18723 | 2.19e-03 | 9.95e-03 | 23 |
GO:00905577 | Oral cavity | OSCC | establishment of endothelial intestinal barrier | 10/7305 | 12/18723 | 2.25e-03 | 1.00e-02 | 10 |
GO:00338654 | Oral cavity | OSCC | nucleoside bisphosphate metabolic process | 66/7305 | 128/18723 | 2.58e-03 | 1.13e-02 | 66 |
GO:00338754 | Oral cavity | OSCC | ribonucleoside bisphosphate metabolic process | 66/7305 | 128/18723 | 2.58e-03 | 1.13e-02 | 66 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FASN | SNV | Missense_Mutation | novel | c.2134T>A | p.Trp712Arg | p.W712R | P49327 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A3XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
FASN | SNV | Missense_Mutation | rs771513967 | c.2635N>C | p.Thr879Pro | p.T879P | P49327 | protein_coding | tolerated(0.05) | benign(0.087) | TCGA-A7-A3IY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
FASN | SNV | Missense_Mutation | | c.6337N>A | p.Glu2113Lys | p.E2113K | P49327 | protein_coding | deleterious(0.02) | possibly_damaging(0.873) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FASN | SNV | Missense_Mutation | | c.5925N>C | p.Leu1975Phe | p.L1975F | P49327 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FASN | SNV | Missense_Mutation | | c.5531N>A | p.Ala1844Asp | p.A1844D | P49327 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FASN | SNV | Missense_Mutation | novel | c.5236N>G | p.Asn1746Asp | p.N1746D | P49327 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
FASN | SNV | Missense_Mutation | rs759072039 | c.410N>A | p.Arg137Gln | p.R137Q | P49327 | protein_coding | deleterious(0.03) | possibly_damaging(0.664) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
FASN | SNV | Missense_Mutation | | c.5302N>A | p.Glu1768Lys | p.E1768K | P49327 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
FASN | SNV | Missense_Mutation | novel | c.4081N>G | p.Thr1361Ala | p.T1361A | P49327 | protein_coding | tolerated(0.13) | benign(0.08) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FASN | SNV | Missense_Mutation | | c.6665N>A | p.Leu2222Gln | p.L2222Q | P49327 | protein_coding | tolerated(0.18) | possibly_damaging(0.732) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | BI-87E7 | CHEMBL523200 | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | GNF-PF-2262 | CHEMBL577862 | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | GNF-PF-1307 | CHEMBL585030 | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | TCMDC-124317 | CHEMBL586937 | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | HEXACHLOROPHENE | HEXACHLOROPHENE | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | Cerulenin | CERULENIN | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | PACLITAXEL | PACLITAXEL | 15657900 |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | LORGLUMIDE SODIUM | LORGLUMIDE SODIUM | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | FSA2 | | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | PYROGALLOL RED | PYROGALLOL RED | |